Victor Li | CEO
Lion TCR | Singapore

Victor Li, CEO, Lion TCR

Dr. Lietao Li is the co-founder, chairman of the board, and CEO of Lion TCR Pte. Ltd.  Dr. Li has over 20 years of biopharmaceutical industrial experience and 4 years of clinical experience. Dr. Li founded his first biotech company specializing in vaccine development, where he served as the executive director and chief scientific officer. He then successfully transferred the company upon accomplishing preclinical studies, pilot GMP production, and the completion of Phase I / II clinical trials for two vaccine candidates. The company was successfully merged with an established vaccine manufacturer. Dr. Li has been awarded with 60 patents as co-inventor. Prior to this, he practiced strategy consulting for the biopharmaceutical industry with PricewaterhouseCoopers as a principal consultant and with Deloitte Consulting as a senior manager. He started his industrial career of multiple functions in medical affairs and marketing strategy with Ciba-Geigy Pharmaceuticals.


Phar-East Day One @ 14:40

Anti-viral immunotherapy: A case study

Chronic viral infection predisposes a person to the development of cancer. The integrated viral genes in infected cells can be expressed to create viral peptides and presented onto the cell surface. Using our proprietary TCR platform, patient’s T cells can be engineered with high-avidity antiviral TCRs which recognize the tumor-specific viral peptides, leading to the release of cytolytic molecules and the lysis of cancer cells.

back to speakers